News

Statement warns of drugs causing or exacerbating heart failure


 

References

Managing myriad meds

The statement also calls for stopping medications without a well defined indication for a patient, avoid prescribing new drugs to address side effects of other drugs, and suggests establishing a “captain” among the health care providers seen by each patient who would be particularly responsible for overseeing and keeping track of the medications the patient takes.

“Ideally, this ‘captain’ would be the patient’s primary care provider, who should be in contact with the other specialists that the patient may be seeing. However, this does not always happen,” said Dr. Page. “Therefore, I encourage each patient with heart failure to contact both their primary care provider and their health care provider who is managing their heart failure before taking or stopping any new medication including prescription, OTC, herbal, complimentary or alternative medication or supplement. Health care providers need to encourage patients to be actively engaged in their medication management.”

Dr. Page had no disclosures.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

AHA: Empagliflozin for T2D reduces heart failure endpoints
MDedge Endocrinology
AHA: Should BP targets be higher in asymptomatic aortic stenosis?
MDedge Endocrinology
FDA cancels REMS for rosiglitazone
MDedge Endocrinology
Primary care endures in heart failure management
MDedge Endocrinology
AHA: Bariatric surgery slashes heart failure exacerbations
MDedge Endocrinology
Two new drugs
MDedge Endocrinology
No LIGHT shed on CV safety of naltrexone-bupropion
MDedge Endocrinology
Incretin-based diabetes drugs don’t raise heart failure risk
MDedge Endocrinology
FDA adds safety warnings to certain type 2 diabetes medications
MDedge Endocrinology
No rise in serious HF seen in patients taking saxagliptin or sitagliptin
MDedge Endocrinology